Cargando…
891. Minimum Manufacturing Costs and National Prices for Weight Loss Treatments, as Potential Mitigation for Anti-Retroviral Related Weight Gain in HIV
BACKGROUND: Weight gain is being observed for a wide range of antiretroviral treatments. Weight gains are higher for people taking first-line integrase inhibitor based treatments, especially those including TAF/FTC. Weight gains are higher for women and people of colour. Clinical obesity increases t...
Autores principales: | Levi, Jacob, Wang, Junzheng, Venter, Francois, Hill, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644642/ http://dx.doi.org/10.1093/ofid/ofab466.1086 |
Ejemplares similares
-
407. Minimum Manufacturing Costs, National Prices and Estimated Global Availability of New Repurposed Therapies for COVID-19
por: Wang, Junzheng, et al.
Publicado: (2021) -
Minimum Manufacturing Costs, National Prices, and Estimated Global Availability of New Repurposed Therapies for Coronavirus Disease 2019
por: Wang, Junzheng, et al.
Publicado: (2021) -
Minimum costs to manufacture new treatments for COVID-19
por: Hill, Andrew, et al.
Publicado: (2020) -
Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19
por: Pepperrell, Toby, et al.
Publicado: (2020) -
Weight gain on dolutegravir: Association is not the same as causation
por: Maartens, Gary, et al.
Publicado: (2023)